Private company

POINT Biopharma Global Inc.

Pharmaceutical preparations company.

Last updated Oct 18, 2026.

Overview

IndustryPharmaceutical Preparations
Business address4850 West 78Th Street, Indianapolis, In 46268²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

55.4%Operating margin³

43.4%Net margin³

20.2%Return on equity³

$170.8MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Research and developmentIncome taxProfit

Research and development36¢$82.1M
Other costs7¢$14.9M
Income tax14¢$31.3M
Profit43¢$98.3M

Out of $226.6M in revenue.³

Where each dollar of operating cash went, fiscal 2022

Kept or used elsewhere

Capital spending7¢$12.8M
Kept or used elsewhere93¢$170.8M

Out of $183.5M of cash from operations.³

Financial statements

Revenue³$226.6M in 2022

Operating income⁴³$125.5M in 2022

Net income⁴³$98.3M in 2022

Fiscal year	2020	2021	2022
Revenue		$0³	$226.6M³
Research and development	$9.1M⁴	$33.5M³	$82.1M³
Operating income	-$13.1M⁴	-$45.5M³	$125.5M³
Income tax	$87.9K⁴	$305.7K³	$31.3M³
Net income	-$13.4M⁴	-$45.9M³	$98.3M³
Earnings per share	-$0.34⁴	-$0.62³	$1.04³
Earnings per share (diluted)	-$0.34⁴	-$0.62³	$1.02³

Total assets⁴³$578.3M in 2022+2506% since 2020

Total liabilities⁴³$91.4M in 2022+949% since 2020

Shareholders’ equity⁴⁷³$487.0M in 2022

Cash⁴³$286.4M in 2022

Fiscal year	2019	2020	2021	2022
Cash	$0⁴	$10.5M⁴	$238.8M³	$286.4M³
Current assets		$12.4M⁴	$243.8M³	$530.8M³
Total assets		$22.2M⁴	$263.3M³	$578.3M³
Current liabilities		$5.2M⁴	$8.0M³	$79.7M³
Total liabilities		$8.7M⁴	$8.0M³	$91.4M³
Shareholders’ equity	-$9.2K⁴	$5.0M⁷	$255.2M³	$487.0M³
Shares outstanding		54.6M shares⁴	90.1M shares³	105.6M shares³

Cash from operations⁴³$183.5M in 2022

Capital spending⁴³$12.8M in 2022+30% since 2020

Free cash flow⁴³$170.8M in 2022

Dividends paid⁴³$0 in 2022

Fiscal year	2020	2021	2022
Cash from operations	-$8.3M⁴	-$44.7M³	$183.5M³
Capital spending	$9.8M⁴	$8.8M³	$12.8M³
Free cash flow	-$18.1M	-$53.5M	$170.8M
Dividends paid	$0⁴	$0³	$0³

Compare POINT Biopharma Global Inc. with another company

Leadership

Who has led POINT Biopharma Global Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Allan C. Silber2022–2023

Chief financial officer

Chief operating officer

Justyna Kelly2021–2023

2025

Chief executive officerJoe A. McCann Jun 30, 2021 to Dec 27, 2023⁸
Chief executive officerPeter Kolchinsky Jul 7, 2020 to Jun 30, 2021⁹
ChairAllan C. Silber Mar 17, 2022 to Dec 27, 2023¹⁰
Chief financial officerWilliam L. Demers Jun 30, 2021 to Dec 27, 2023¹¹
Chief financial officerMatthew Hammond Jul 7, 2020 to Jul 7, 2020¹²
Chief operating officerJustyna Kelly Dec 10, 2021 to Dec 27, 2023¹³

Board members and other officers (14)

Chief Medical OfficerNeil E. Fleshner Jun 30, 2021 to Dec 27, 2023¹⁴
Board memberBridget A. Martell Jun 14, 2023 to Jun 14, 2023¹⁵
Board memberRajeev M. Shah Jun 24, 2021 to Jun 30, 2021¹⁶
Board memberAllan C. Silber Jun 30, 2021 to Feb 14, 2022¹⁷
Board memberGerald L. Hogue Jun 30, 2021 to Dec 27, 2023¹⁸
Board memberJoe A. McCann Jun 30, 2021 to Dec 27, 2023⁸
Board memberMargaret E. Gilmour Jun 30, 2021 to Jul 8, 2021¹⁹
Board memberNeil E. Fleshner Jun 30, 2021 to Dec 27, 2023¹⁴
Board memberRajesh Malik Jun 30, 2021 to Dec 27, 2023²⁰
Board memberYael Margolin Jun 30, 2021 to Dec 27, 2023²¹
Board memberDaniel Grau Jul 7, 2020 to Jul 7, 2020²²
Board memberDavid Charles Lubner Jul 7, 2020 to Dec 27, 2023²³
Board memberMatthew Hammond Jul 7, 2020 to Jul 7, 2020¹²
Board memberPeter Kolchinsky Jul 7, 2020 to Jun 30, 2021⁹

Former names

Therapeutics Acquisition Corp.May 14, 2020 to Jun 30, 2021²

Timeline

Jun 30, 2021New chief executive Joe A. McCann becomes CEO⁸
Jul 7, 2020New chief executive Peter Kolchinsky becomes CEO⁹

Filings

147 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 20 major events, 55 insider forms, 19 large holders, 44 other. The latest 20:

The 147 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 19 such filings since October 2021, the latest 10:

Dec 27, 2023SC 13D/A
Dec 20, 2023SC 13D/A
Nov 6, 2023SC 13D
Oct 3, 2023SC 13D/A
Feb 14, 2023SC 13G/A
Nov 22, 2022SC 13D/A
Sep 26, 2022SC 13D/A
Sep 26, 2022SC 13G
Sep 16, 2022SC 13D/A
Aug 29, 2022SC 13D/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARPOINT Biopharma Global Inc. filings on SEC EDGAR
2
SEC EDGARPOINT Biopharma Global Inc. filings on SEC EDGAR
3
SEC EDGARPOINT Biopharma Global Inc. 10-K for fiscal 2022
4
SEC EDGARPOINT Biopharma Global Inc. 10-K for fiscal 2020
5
SEC EDGARPOINT Biopharma Global Inc. 10-Q for fiscal 2023
6
SEC EDGARPOINT Biopharma Global Inc. 10-Q for fiscal 2023
7
SEC EDGARPOINT Biopharma Global Inc. 10-K for fiscal 2020
8
SEC EDGARJoe A. McCann, Chief executive officer
9
SEC EDGARPeter Kolchinsky, Chief executive officer
10
SEC EDGARAllan C. Silber, Chair
11
SEC EDGARWilliam L. Demers, Chief financial officer
12
SEC EDGARMatthew Hammond, Chief financial officer
13
SEC EDGARJustyna Kelly, Chief operating officer
14
SEC EDGARNeil E. Fleshner, Chief Medical Officer
15
SEC EDGARBridget A. Martell, Board member
16
SEC EDGARRajeev M. Shah, Board member
17
SEC EDGARAllan C. Silber, Board member
18
SEC EDGARGerald L. Hogue, Board member
19
SEC EDGARMargaret E. Gilmour, Board member
20
SEC EDGARRajesh Malik, Board member
21
SEC EDGARYael Margolin, Board member
22
SEC EDGARDaniel Grau, Board member
23
SEC EDGARDavid Charles Lubner, Board member